Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

This study is looking for men aged 18 to 99 who have advanced prostate cancer that has spread and is resistant to hormone treatment. You must have been previously treated with at least one type of hormone-blocking medicine, such as enzalutamide or abiraterone, and your cancer must have continued to grow despite this treatment.

It's important that you are generally well enough to take part, meaning you can look after yourself and manage daily activities, and doctors expect you to live for at least three more months. Your body's organs, like your liver, kidneys, and bone marrow, need to be working well. The cancer should also be visible on scans, and you must have some areas where the cancer has spread that cannot be surgically removed.

For a specific part of the study, your cancer will need to show up on special scans that detect a particular marker called PSMA, with all treatable cancer spots being PSMA positive. You also need to be able to take medicines by mouth, if required.

If you join this study, you will receive one of the new study medicines, either alone or in combination, or standard chemotherapy, depending on which part of the study you are in. You will have regular hospital visits for check-ups, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. Doctors will carefully watch for any side effects and adjust your care as needed.

The study involves different phases: an initial phase to find the safest and most effective dose, followed by a phase to further confirm these findings and gather more information on the treatment's effect. The exact number of visits, tests, and total duration will depend on which treatment you receive and how your body responds; this will be fully explained before you decide to join. If you are sexually active and your partner could become pregnant, you will need to use contraception.